These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11744606)

  • 1. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
    Hill G; Cihlar T; Oo C; Ho ES; Prior K; Wiltshire H; Barrett J; Liu B; Ward P
    Drug Metab Dispos; 2002 Jan; 30(1):13-9. PubMed ID: 11744606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
    He G; Massarella J; Ward P
    Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4).
    Ose A; Ito M; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Hosokawa M; Schuetz JD; Sugiyama Y
    Drug Metab Dispos; 2009 Feb; 37(2):315-21. PubMed ID: 19029202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
    Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
    Ito M; Kusuhara H; Ose A; Kondo T; Tanabe K; Nakayama H; Horita S; Fujita T; Sugiyama Y
    AAPS J; 2017 Jan; 19(1):286-297. PubMed ID: 27800573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir: a clinical and pharmacological perspective.
    Doucette KE; Aoki FY
    Expert Opin Pharmacother; 2001 Oct; 2(10):1671-83. PubMed ID: 11825310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
    Morimoto K; Kishimura K; Nagami T; Kodama N; Ogama Y; Yokoyama M; Toda S; Chiyoda T; Shimada R; Inano A; Kano T; Tamai I; Ogihara T
    J Pharm Sci; 2011 Sep; 100(9):3854-61. PubMed ID: 21607954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
    Morimoto K; Nagami T; Matsumoto N; Wada S; Kano T; Kakinuma C; Ogihara T
    J Toxicol Sci; 2012; 37(6):1217-23. PubMed ID: 23208436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.
    Mathialagan S; Piotrowski MA; Tess DA; Feng B; Litchfield J; Varma MV
    Drug Metab Dispos; 2017 Apr; 45(4):409-417. PubMed ID: 28179375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
    Wiltshire H; Wiltshire B; Citron A; Clarke T; Serpe C; Gray D; Herron W
    J Chromatogr B Biomed Sci Appl; 2000 Aug; 745(2):373-88. PubMed ID: 11043756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
    Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
    Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice.
    Hatori A; Arai T; Yanamoto K; Yamasaki T; Kawamura K; Yui J; Konno F; Nakao R; Suzuki K; Zhang MR
    Nucl Med Biol; 2009 Jan; 36(1):47-55. PubMed ID: 19181268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
    Sweeny DJ; Lynch G; Bidgood AM; Lew W; Wang KY; Cundy KC
    Drug Metab Dispos; 2000 Jul; 28(7):737-41. PubMed ID: 10859145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.
    Mandíková J; Volková M; Pávek P; Česnek M; Janeba Z; Kubíček V; Trejtnar F
    Toxicology; 2013 Sep; 311(3):135-46. PubMed ID: 23856525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir.
    Bardsley-Elliot A; Noble S
    Drugs; 1999 Nov; 58(5):851-60; discussion 861-2. PubMed ID: 10595865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oseltamivir: a review of its use in influenza.
    McClellan K; Perry CM
    Drugs; 2001; 61(2):263-83. PubMed ID: 11270942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
    Chu XY; Bleasby K; Yabut J; Cai X; Chan GH; Hafey MJ; Xu S; Bergman AJ; Braun MP; Dean DC; Evers R
    J Pharmacol Exp Ther; 2007 May; 321(2):673-83. PubMed ID: 17314201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.